Wedbush Weighs in on Ardelyx's Q4 Earnings (NASDAQ:ARDX)

Ardelyx, Inc. (NASDAQ:ARDX - Free Report) - Equities research analysts at Wedbush boosted their Q4 2025 EPS estimates for Ardelyx in a report issued on Friday, May 2nd. Wedbush analyst L. Chico now forecasts that the biopharmaceutical company will post earnings of $0.01 per share for the quarter, up from their previous forecast of ($0.01). The consensus estimate for Ardelyx's current full-year earnings is ($0.18) per share. Wedbush also issued estimates for Ardelyx's FY2026 earnings at $0.08 EPS and FY2029 earnings at $0.89 EPS.

Several other brokerages have also recently issued reports on ARDX. Raymond James cut shares of Ardelyx from a "strong-buy" rating to an "outperform" rating and set a $11.00 price target on the stock. in a research report on Friday. Scotiabank started coverage on Ardelyx in a research note on Friday, March 7th. They issued a "sector outperform" rating and a $15.00 price target for the company. BTIG Research started coverage on shares of Ardelyx in a research report on Tuesday, March 4th. They set a "buy" rating and a $14.00 price objective on the stock. Cantor Fitzgerald raised Ardelyx to a "strong-buy" rating in a report on Tuesday, March 4th. Finally, Citigroup dropped their price target on shares of Ardelyx from $11.00 to $10.00 and set a "buy" rating on the stock in a research note on Friday. Three analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $10.39.

Ardelyx Price Performance

ARDX opened at $4.13 on Monday. The company has a debt-to-equity ratio of 0.87, a quick ratio of 4.31 and a current ratio of 4.58. The stock's 50 day moving average price is $5.00 and its 200-day moving average price is $5.24. The stock has a market capitalization of $984.41 million, a PE ratio of -25.81 and a beta of 0.76. Ardelyx has a 52-week low of $4.02 and a 52-week high of $9.33.

Ardelyx (NASDAQ:ARDX - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.07). The firm had revenue of $74.11 million during the quarter, compared to the consensus estimate of $79.40 million. Ardelyx had a negative return on equity of 24.87% and a negative net margin of 11.73%. Ardelyx's revenue was up 61.1% on a year-over-year basis. During the same period last year, the business earned ($0.11) EPS.

Institutional Investors Weigh In On Ardelyx

Institutional investors and hedge funds have recently modified their holdings of the business. JPMorgan Chase & Co. grew its stake in Ardelyx by 1.6% in the third quarter. JPMorgan Chase & Co. now owns 387,144 shares of the biopharmaceutical company's stock worth $2,667,000 after purchasing an additional 6,093 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Ardelyx by 5.6% during the fourth quarter. Vanguard Group Inc. now owns 14,362,659 shares of the biopharmaceutical company's stock worth $72,819,000 after purchasing an additional 767,111 shares during the period. Barclays PLC grew its position in Ardelyx by 24.9% during the 3rd quarter. Barclays PLC now owns 547,325 shares of the biopharmaceutical company's stock worth $3,770,000 after purchasing an additional 109,285 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in shares of Ardelyx by 5.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,035,135 shares of the biopharmaceutical company's stock valued at $10,318,000 after purchasing an additional 96,357 shares in the last quarter. Finally, Rhumbline Advisers raised its holdings in Ardelyx by 1.9% in the 4th quarter. Rhumbline Advisers now owns 326,124 shares of the biopharmaceutical company's stock worth $1,653,000 after purchasing an additional 6,070 shares during the period. 58.92% of the stock is owned by institutional investors.

Insider Buying and Selling at Ardelyx

In related news, Director David M. Mott acquired 77,729 shares of Ardelyx stock in a transaction on Monday, February 24th. The shares were bought at an average cost of $5.00 per share, with a total value of $388,645.00. Following the completion of the purchase, the director now directly owns 2,015,494 shares of the company's stock, valued at $10,077,470. The trade was a 4.01 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Michael Raab sold 41,666 shares of the business's stock in a transaction that occurred on Friday, April 4th. The shares were sold at an average price of $4.59, for a total value of $191,246.94. Following the transaction, the chief executive officer now directly owns 1,615,587 shares in the company, valued at approximately $7,415,544.33. This represents a 2.51 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 116,410 shares of company stock worth $600,475. Insiders own 5.90% of the company's stock.

About Ardelyx

Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.